Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 841

Sort by

Sort Order Select

Journal Articles

The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health

Chia-Yau Chang, MD, Yeu-Chin Chen, MD, Chen-Hua Tsai, MD, Jia-Ruey Tsai, MD, Yen-Lin Liu, MD, Shu-Hsia Hu

Blood (2019) 134 (Supplement_1): 2406.

https://doi.org/10.1182/blood-2019-132137

Published: 2019

Journal Articles

Rivaroxaban Reduces the Levels of Extracellular Vesicles in Patients with Venous Thromboembolism and Non-Valvular Atrial Fibrillation

Sarah Kelliher, MBBS, Luisa Weiss, MSc, Paulina Szklanna, PhD, Karl Egan, PhD, Tadhg Prendiville, MB BCh BAO, Eric Moran, MB BCh BAO, Georgi Petrov, MB BCh BAO, Alfonso Blanco, PhD, Aine Lennon, MSc, Sean Murphy, MD, John Keaney, MD, Fionnuala Ni Ainle, PhD, Patricia Maguire, PhD

Blood (2019) 134 (Supplement_1): 2437.

https://doi.org/10.1182/blood-2019-126166

Published: 2019

Journal Articles

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Katarzyna Aleksandra Jalowiec, Thomas Pabst, MD, Christoph Bocksrucker, Claudio Brunold, Barbara Jeker, Gabriela M Baerlocher, MD, Urban Novak, Ulrike Bacher, Michael Daskalakis, MD, Behrouz Mansouri, MD, Sacha S Zeerleder, MD PhD

Blood (2019) 134 (Supplement_1): 2457.

https://doi.org/10.1182/blood-2019-126534

Published: 2019

Journal Articles

Allo-Immunisation in Sickle Cell Patients in a Large British Specialist Haemoglobinopathy Centre

Sarrah Tayabali, MBBS, BSc, DipRCPath, Karen Madgwick, FIBMS, CSci, DMLM, PgDip, Arne de Kreuk, MD PhD

Blood (2019) 134 (Supplement_1): 2451.

https://doi.org/10.1182/blood-2019-130492

Published: 2019

Journal Articles

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Samah Nassereddine, MD, Kimberley Doucette, MD MSc, Vanya Aggarwal, Richard Amdur, PhD, Imad A. Tabbara, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 2212.

https://doi.org/10.1182/blood-2019-124150

Published: 2019

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

Echocardiographic Probability of Pulmonary Hypertension in Myeloproliferative Neoplasms Patients in Chiang-Mai University

Yanika Jindamai, MD, Ekarat Rattarittamrong, MD, Arintaya Phrommintikul, MD, Lalita Yongsmith, MD, Thanawat Rattanathammethee, MD, Chatree Chai-Adisaksopha, MD PhD, Adisak Tantiworawit, MD, Lalita Norasetthada, MD

Blood (2019) 134 (Supplement_1): 5390.

https://doi.org/10.1182/blood-2019-126599

Published: 2019

Journal Articles

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Blood (2019) 134 (Supplement_1): 5249.

https://doi.org/10.1182/blood-2019-125921

Published: 2019

Journal Articles

Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients

Masaaki Hotta, MD, Satake Atsushi, MD PhD, Yukie Tsubokura, MD, Yoshiko Azuma, MD, Hideaki Yoshimura, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Tomoki Ito, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2019) 134 (Supplement_1): 5672.

https://doi.org/10.1182/blood-2019-129959

Published: 2019

Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Blood (2019) 134 (Supplement_1): 4296.

https://doi.org/10.1182/blood-2019-128470

Published: 2019

Journal Articles

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Tim H Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Camille Abboud, MD, Justin M. Watts, MD, Gianantonio Rosti, MD, Alexander Russell-Smith, Andrea Viqueira, MD, Arlene Reisman, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 4157.

https://doi.org/10.1182/blood-2019-124344

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Carlo Gambacorti-Passerini, MD, Tim H Brümmendorf, MD, Bjorn T. Gjertsen, MD PhD, Camille Abboud, MD, Gianantonio Rosti, MD, Elisabetta Abruzzese, MD, Eric Leip, PhD, Andrea Viqueira, MD, Valentín García Gutiérrez, PhD, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 2936.

https://doi.org/10.1182/blood-2019-121813

Published: 2019

Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Blood (2019) 134 (Supplement_1): 3943.

https://doi.org/10.1182/blood-2019-128683

Published: 2019

Journal Articles

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Pau Abrisqueta, MD PhD, Juan-Manuel Sancho, MD PhD, Raul Cordoba, MD PhD, Daniel O. Persky, MD, Charalambos Andreadis, MD MSCE, Scott F. Huntington, MD MPH, Cecilia Carpio, MD, Daniel Morillo Giles, MD, Xin Wei, PhD, Ying Fei Li, PhD, Marlene Zuraek, MD, Michael R. Burgess, Kristen Hege, Alejandro Martín, MD PhD

Blood (2019) 134 (Supplement_1): 4089.

https://doi.org/10.1182/blood-2019-125310

Published: 2019

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

https://doi.org/10.1182/blood-2019-125423

Published: 2019

Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 87.

https://doi.org/10.1182/blood-2019-122336

Published: 2019

Journal Articles

Role of High-Dose Melphalan and Autologous Stem Cell Transplantation in Multiple Myeloma Patients Presenting with t(11;14)

Blood (2019) 134 (Supplement_1): 4580.

https://doi.org/10.1182/blood-2019-129880

Published: 2019

Journal Articles

Clinical Features of Post-Transplant Lymphoproliferative Disease Are Different between Kidney-Transplant Recipients from a Cadaveric Donor and Those from a Living Donor

Shoko Oshima, MD, Akihito Shinohara, MD, Hideki Ishida, MD PhD, Miki Umeda, MD, Satoko Osanai, MD, Satoru Itoi, MD, Michiko Ryuzaki, MD, Yuki Izuka, MD, Aya Watanabe, MD, Norina Tanaka, MD PhD, Midori Ishiyama, MD PhD, Hiroshi Kazama, MD PhD, Kentaro Yoshinaga, MD PhD, Shotaro Hagiwara, MD PhD, Masayuki Shiseki, MD PhD, Junji Tanaka, MD PhD

Blood (2019) 134 (Supplement_1): 2910.

https://doi.org/10.1182/blood-2019-125601

Published: 2019

Journal Articles

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Univ. Prof. Dr., Florian H. Heidel, Philippe Schafhausen, Martin Griesshammer, MD, Denise Wolleschak, Uwe Platzbecker, Konstanze Döhner, Philipp J. Jost, MD, Stefani B. Parmentier, Nikolas von Bubnoff, Frank Stegelmann, MD, Angela Maurer, Jeremy Franklin, Martina Crysandt, MD, Deniz Gezer, Martin Hellmich, Tim H Brümmendorf, MD

Blood (2019) 134 (Supplement_1): 2944.

https://doi.org/10.1182/blood-2019-123985

Published: 2019

NARROW

The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health

Rivaroxaban Reduces the Levels of Extracellular Vesicles in Patients with Venous Thromboembolism and Non-Valvular Atrial Fibrillation

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Allo-Immunisation in Sickle Cell Patients in a Large British Specialist Haemoglobinopathy Centre

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Echocardiographic Probability of Pulmonary Hypertension in Myeloproliferative Neoplasms Patients in Chiang-Mai University

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

Role of High-Dose Melphalan and Autologous Stem Cell Transplantation in Multiple Myeloma Patients Presenting with t(11;14)

Clinical Features of Post-Transplant Lymphoproliferative Disease Are Different between Kidney-Transplant Recipients from a Cadaveric Donor and Those from a Living Donor

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only